drugset / Trial / NCT06342349
A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.
Phase 1
Completed
300 enrolled
Shanghai Institute Of Biological Products
Shaanxi Provincial Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
To evaluate the safety of administering 1 or 2 doses of the quadrivalent influenza virus split vaccine (MDCK cells) (0.5ml/dose) in individuals aged 6 months and above.
Timeline
- Start
- 2024-03-30
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Quadrivalent influenza virus split vaccine (Chicken embryo) | Vaccine | 0.5 ml | — |
| Subject | Quadrivalent influenza virus split vaccine (MDCK cells) | Vaccine | 0.5 ml | — |